Quick answer
What parameters have BPC-157 preclinical studies reported? The rat Achilles tendon studies reported 10 µg, 10 ng and 10 pg per kilogram given intraperitoneally once daily from 30 minutes after surgery, with saline controls; cell studies used dose- and time-dependent series. These are descriptions of published designs, not recommendations. For laboratory work, fix a working concentration, derive stock and dilution with c = m ÷ V, correct for net peptide content, and run vehicle and scrambled-peptide controls. The reconstitution calculator handles the arithmetic.
Papers on BPC-157 report their experimental parameters in a way that is easy to misread: amounts are given per kilogram of body weight, routes are named in shorthand, schedules are expressed relative to the moment of injury, and the same few laboratories use the same designs repeatedly. This article reads that literature as a methods exercise. It lists what the cited preclinical studies reported, describes how an in-vitro experiment with the lyophilized peptide turns a reported concentration into a working stock, and flags design questions that the published work leaves open. It does not recommend any amount for any purpose; all material discussed is for laboratory research use only, and nothing here applies to people.
What the published studies actually specify
The most-cited animal studies share a template. In the transected rat Achilles tendon model (Staresinic et al., 2003) the peptide was dissolved in saline with no carrier and given intraperitoneally once daily at three amounts per kilogram of body weight, 10 µg, 10 ng and 10 pg, with a saline control; the first administration came 30 minutes after surgery and the last 24 hours before analysis, and outcomes were read on days 1, 4, 7, 10 and 14. The tendon-to-bone detachment study (Krivic et al., 2006) used the same three amounts, the same route and schedule, a corticosteroid comparator and a saline control, and read outcomes at days 1 to 21.
Two things stand out. The amounts span nine orders of magnitude within a single experiment, so the studies were describing a very wide window rather than a narrow optimum. And the studies report the amounts relative to body weight and not as concentrations, which means the numbers cannot be transferred to a cell-culture experiment without a model of distribution that the papers do not provide.
| Study | System | Route and schedule as reported | Parameter range reported |
|---|---|---|---|
| Staresinic et al., 2003 | Transected rat Achilles tendon; cultured tendocytes | Intraperitoneal, once daily, first at 30 min after surgery, last 24 h before analysis | 10 µg, 10 ng and 10 pg per kg; saline control |
| Krivic et al., 2006 | Rat Achilles tendon detached from bone | Intraperitoneal, once daily, same timing | 10 µg, 10 ng and 10 pg per kg; corticosteroid and saline comparators |
| Chang et al., 2011 | Tendon explants and rat tendon fibroblasts in culture | Added to culture medium | Dose-dependent responses reported across a concentration series (see paper for values) |
| Chang et al., 2014 | Rat tendon fibroblasts in culture | Added to culture medium | Dose- and time-dependent changes in receptor expression |
| Hsieh et al., 2017 | Chick chorioallantoic membrane, endothelial tube formation, rat hind-limb ischemia, human endothelial cells | Model-specific; see paper | Concentration and time series reported per model |
The table deliberately records the structure of each design and points to the paper for numeric values it does not reproduce here. Anyone planning work from the literature should read the methods section of the original paper and check units, vehicle and timing before borrowing a figure.
In-vitro designs: concentration series, time courses and controls
In culture, the Chang studies show the design that most laboratories can reproduce. The 2011 paper examined tendon explant outgrowth, cell survival under hydrogen peroxide stress, transwell migration, spreading, F-actin staining and phosphorylation of FAK and paxillin, using dose-dependent series; it reported that proliferation by MTT assay was not directly affected, which is an instructive negative result because it tells the reader which readouts did not move. The 2014 paper used cDNA microarray to find that growth hormone receptor was among the most up-regulated genes, then confirmed it by RT-PCR and Western blot over doses and times, and added growth hormone to ask whether the up-regulated receptor was functional.
Design features worth copying are the pairing of a discovery step (array) with orthogonal confirmation (mRNA and protein), the use of both dose and time series, and the inclusion of a functional follow-up. Design features worth questioning are the limited number of cell sources, the absence of a scrambled or inactive peptide control in most reports, and the reliance on a single vendor-neutral readout per mechanism. A good control set for any new BPC-157 cell experiment includes a vehicle control matched to the diluent, a scrambled-sequence peptide at the same concentration, a positive control for the pathway under study, and a lot-matched untreated arm. Cell-based work with the peptide begins with a defined stock; the method for making one is in how to reconstitute a lyophilized peptide.
Turning a reported concentration into a stock: the arithmetic
A reported working concentration becomes a bench plan through a few relationships. Nothing here is specific to one compound, and no per-vial figures are given because the numbers depend on the stock the experiment calls for.
| Step | Formula | Comment |
|---|---|---|
| Pick the working concentration | c(work), from the experimental design | State units explicitly: µg/mL, µM or nM |
| Convert mass to moles | n (mmol) = m (mg) ÷ MW (g/mol) | MW of BPC-157 is about 1419.5 g/mol (C62H98N16O22) |
| Stock concentration | c(stock) = m ÷ V | Choose a stock at least 100 to 1000 times the working concentration so the vehicle stays a small fraction of the culture volume |
| Dilution | V(stock to add) = c(work) × V(final) ÷ c(stock) | Check that the added volume is practical to pipette accurately |
| Vehicle fraction | f = V(stock to add) ÷ V(final) | Keep identical in every arm, including controls |
Two corrections apply. The labeled vial mass includes counterions and residual water, so net peptide content is below the labeled mass; for concentration-critical work, quantify the stock. And a dilute working solution loses peptide to plastic, so the delivered concentration can be lower than the calculated one; see the adsorption notes in the storage guides. The reconstitution calculator handles the unit conversions and the volume calculation guide shows worked examples of the method.
What animal-model parameters imply for study design
Reading the animal studies as design templates raises four questions. Timing relative to injury: the Achilles studies begin 30 minutes after surgery, which tests an early intervention and says little about delayed administration. Route: intraperitoneal administration delivers the peptide to the systemic circulation; local, oral, intravenous and topical routes appear elsewhere in the literature and are not interchangeable, so a result in one route cannot be assumed for another. Vehicle: the tendon papers dissolved the peptide in saline without a carrier, which simplifies interpretation of the vehicle control. Endpoints: the tendon work combined functional indices, biomechanical testing (load to failure, stiffness, Young’s modulus), histology and immunohistochemistry, an unusually multi-layered set that makes agreement between readouts informative.
The systematic review of Vasireddi and colleagues (2025) pooled 35 preclinical studies and one clinical study and concluded that the preclinical results were favorable across muscle, tendon, ligament and bone models, while noting that the evidence base is limited by its small number of laboratories and by the lack of human data. Gwyer and colleagues (2019) reach a similar conclusion, adding that only a handful of research groups have performed in-depth studies. For a new laboratory, those observations translate into a practical rule: independent replication with a fully documented lot is worth more than another variation on a published design.
Reporting standards that make a BPC-157 study reproducible
A study that uses a commercially sourced research peptide should report, at minimum, the sequence and the form (free base or salt), the lot number, the purity method and value with a reference to the certificate, the solvent and its lot, the stock concentration and how it was verified, storage and thaw history, the vehicle control and the number of independent experiments. Journals increasingly request such details, and omitting them is the single most common reason a peptide result cannot be reproduced.
| Report item | Why it matters |
|---|---|
| Salt form and counterion | Changes mass per mole of active peptide |
| Lot number and certificate reference | Lets another laboratory obtain comparable material |
| Purity method (for example HPLC) and value | Chromatographic purity is not net peptide content |
| Identity confirmation | Sequence confirmation is distinct from purity |
| Stock verification | Calculated and measured concentration can differ |
| Storage and thaw history | Freeze–thaw and time in solution affect the sample |
| Replicates and controls | Separates peptide effects from vehicle and handling |
For help reading the purity and identity documents, see how to read a COA and understanding HPLC purity; certificates that have been published are in the COA library. The wider literature context is in the BPC-157 research overview and the comparison with a different peptide in BPC-157 vs TB-500.
Frequently asked questions
What amounts did the BPC-157 tendon studies use?
The rat Achilles studies from Staresinic et al. (2003) and Krivic et al. (2006) reported 10 µg, 10 ng and 10 pg per kilogram of body weight, given intraperitoneally once daily with a saline control. These are reported experimental parameters, not recommendations.
Why do the studies report per-kilogram amounts and not concentrations?
Animal studies describe the quantity administered relative to body weight. Those figures do not translate to a cell-culture concentration without distribution data that the papers do not supply.
How do I convert a published in-vitro concentration into a stock?
Fix the working concentration, choose a stock 100 to 1000 times higher, and compute the volume to add from c(work) × V(final) ÷ c(stock). Use MW ≈ 1419.5 g/mol for molar conversions.
Does HPLC purity change the stock concentration calculation?
It can. Labeled mass includes counterions and residual water, so net peptide content is lower than the labeled mass. Quantify the stock when concentration is critical.
Which controls should a BPC-157 cell experiment include?
A diluent-matched vehicle control, a scrambled-sequence peptide at the same concentration, a pathway-specific positive control and a lot-matched untreated arm.
Did BPC-157 change tendon fibroblast proliferation in culture?
The 2011 study reported that proliferation by MTT assay was not directly affected, while outgrowth from explants, survival under peroxide stress and migration increased.
Is the route of administration interchangeable between studies?
No. Intraperitoneal, local, oral and other routes appear in the literature, and a result under one route should not be assumed for another.
How many studies are in the 2025 systematic review?
Thirty-six: 35 preclinical studies and one clinical study, identified from 544 articles published between 1993 and 2024.
Is there an optimal amount for study design?
The published tendon work spans nine orders of magnitude within a single experiment and does not identify a single optimum. Any choice should be justified by pilot data in the laboratory’s own system.
What should I record about the peptide lot in a methods section?
Sequence, salt form, lot number, purity method and value, identity confirmation, solvent, stock concentration and verification, and storage and thaw history.
Related reading: BPC-157 Preclinical Safety Profile: What Studies Report, BPC-157 Tendon Research: Rat and Cell Studies Explained, BPC-157 Gastrointestinal Animal Research: A Model Map.
References
- Staresinic M, Petrovic I, Novinscak T, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4
- Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. doi:10.1002/jor.20096
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
- Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066
- Hsieh MJ, Lee CH, Chueh HY, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8
